Abstract:Nanoscale pulldown (NanoSPD) miniaturizes the concept of affinity pulldown to detect protein–protein interactions in live cells. NanoSPD hijacks the myosin-based intracellular trafficking machinery to assess interactions under physiological buffer conditions and is microscopy-based, allowing for sensitive detection and quantification.
“…The images were converted to tagged image file format (TIFF). Filopodia were then selected and signals at their tips quantified using the FIJI-based procedure and MATLAB software described by Bird and colleagues (NanoSPD [48]). 33 cells representing 3 independent experiments were selected for each condition, and 126 (MYC) versus 225 (MYC:GPSM2) filopodia that passed the selection process were analyzed.…”
GPSM2-GNAI Specifies the Tallest Stereocilia and Defines Hair Bundle Row Identity Highlights d GPSM2, GNAI, WHRN, MYO15A, and EPS8 work in the same pathway to shape hair bundles d GPSM2-GNAI-WHRN is a late module added to MYO15A-EPS8 at row 1 stereocilia tips only d GPSM2-GNAI defines the identity of the tallest, first-row stereocilia d Mutant bundles comprise generic stereocilia lacking differential row identity
“…The images were converted to tagged image file format (TIFF). Filopodia were then selected and signals at their tips quantified using the FIJI-based procedure and MATLAB software described by Bird and colleagues (NanoSPD [48]). 33 cells representing 3 independent experiments were selected for each condition, and 126 (MYC) versus 225 (MYC:GPSM2) filopodia that passed the selection process were analyzed.…”
GPSM2-GNAI Specifies the Tallest Stereocilia and Defines Hair Bundle Row Identity Highlights d GPSM2, GNAI, WHRN, MYO15A, and EPS8 work in the same pathway to shape hair bundles d GPSM2-GNAI-WHRN is a late module added to MYO15A-EPS8 at row 1 stereocilia tips only d GPSM2-GNAI defines the identity of the tallest, first-row stereocilia d Mutant bundles comprise generic stereocilia lacking differential row identity
“…Eventually, Chd7 expression becomes enriched in specific cells and tissues, especially in organs where malformations are known to occur in CHARGE. CHD7 is localized primarily to the nucleus, although a recent study suggested it may also localize to inner ear stereocilia [Bird et al, 2017]. Chd7 expression in mouse neural tissues likely reflects its important functions in a wide variety of peripheral and central nervous system regions.…”
The inner ear contains the sensory organs for hearing and balance. Both hearing and balance are commonly affected in individuals with CHARGE syndrome (CS), an autosomal dominant condition caused by heterozygous pathogenic variants in the CHD7 gene. Semicircular canal dysplasia or aplasia is the single most prevalent feature in individuals with CHARGE leading to deficient gross motor skills and ambulation. Identification of CHD7 as the major gene affected in CHARGE has enabled acceleration of research in this field. Great progress has been made in understanding the role of CHD7 in the development and function of the inner ear, as well as in related organs such as the middle ear and auditory and vestibular neural pathways. The goals of current research on CHD7 and CS are to (a) improve our understanding of the pathology caused by CHD7 pathogenic variants and (b) to provide better tools for prognosis and treatment. Current studies utilize cells and whole animals, from flies to mammals. The mouse is an excellent model for exploring mechanisms of Chd7 function in the ear, given the evolutionary conservation of ear structure, function, Chd7 expression, and similarity of mutant phenotypes between mice and humans. Newly recognized developmental functions for mouse Chd7 are shedding light on how abnormalities in CHD7 might lead to CS symptoms in humans. Here we review known human inner ear phenotypes associated with CHD7 pathogenic variants and CS, summarize progress toward diagnosis and treatment of inner ear-related pathologies, and explore new avenues for treatment based on basic science discoveries.
“…To further explore the molecular mechanism of CIB2-mediated mTORC1 modulation, we assessed direct interactions between CIB2 and TSC1, TSC2, mTORC1-specifc subunit Raptor, mTOR kinase, and Rheb, using a previously reported nanoscale pulldown 2.0 (NanoSPD) quantitative interaction assay 32 . NanoSPD utilizes a construct (nanoTRAP) consisting of GFP nanobody fused with the heavy meromyosin (HMM domain) of myosin 10 (myo10 HMM -GFP nanobody).…”
Section: Cib2 Forms a Tripartite Complex With Raptor-mtormentioning
SUMMARYAge-related macular degeneration (AMD), a multifactorial neurodegenerative disorder, is the most common cause of vision loss in the elderly. Deficits in autophagy have been associated with age-related retinal pigment epithelium (RPE) pathology in mice, and dry-AMD in humans. In this study, we establish that the calcium and integrin binding protein 2 (CIB2) regulates autophagy in the RPE via Rheb-mTORC1 signaling axis. Cib2 mutant mice have reduced autophagic clearance in RPE and increased mTORC1 signaling – a negative regulator of autophagy. Concordant molecular deficits were also observed in RPE/choroid tissues from humans affected with dry AMD. Mechanistically, CIB2 negatively regulates mTORC1 by preferentially binding to ‘nucleotide empty’ or inactive GDP-loaded Rheb. Upregulated mTORC1 signaling has been implicated in aging, Tuberous sclerosis complex (TSC), and lymphangioleiomyomatosis (LAM) cancer. Over-expressing CIB2 in LAM patient-derived fibroblasts and Tsc2 null cell line down-regulates hyperactive mTORC1 signaling. Thus, our findings have significant ramifications for the etiology of AMD and mTORC1 hyperactivity disorders and treatments.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.